Halozyme Stock Surges As AbbVie Deal Pays Off

By | August 11, 2015

Scalper1 News

Biotech Halozyme Therapeutics (HALO) jumped 16% early Tuesday, nearly touching an all-time high, a day after the company beat Q2 estimates and provided an update on its pipeline. Late Monday, Halozyme reported revenue of $43.4 million, up 136% from the year-earlier quarter and $18 million more than analysts expected. More than half the revenue came from a $23 million milestone payment from AbbVie (ABBV) in June. A partnership between the two Scalper1 News

Scalper1 News